Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Assessing the economic va… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA(1c), weight and hypoglycaemic event incidence

Artikel i vetenskaplig tidskrift
Författare P. McEwan
H. Bennett
Kristian Bolin
M. Evans
Publicerad i Diabetic Medicine
Volym 35
Nummer/häfte 5
Sidor 557-566
ISSN 0742-3071
Publiceringsår 2018
Publicerad vid Centrum för hälsoekonomi (CHEGU)
Sidor 557-566
Språk en
Länkar doi.org/10.1111/dme.13590
Ämnesord glycemic control, cardiovascular-disease, cost-effectiveness, model, complications, mellitus, cohort, risk, duration, therapy, Endocrinology & Metabolism
Ämneskategorier Endokrinologi och diabetes

Sammanfattning

AimsInsulin therapy is indicated for people with Type 1 diabetes mellitus; however, treatment-related weight gain and hypoglycaemia represent barriers to optimal glycaemic management. This study assessed the health economic value of maintained reductions in HbA(1c), BMI and hypoglycaemia incidence among the UK Type 1 diabetes population. MethodsThe Cardiff Type 1 Diabetes Model was used to estimate lifetime costs, life-years and quality-adjusted life-years (QALYs) for individuals with Type 1 diabetes at different baseline HbA(1c), BMI and hypoglycaemic event rates. Results were discounted at 3.5%, and the net monetary benefit associated with improving Type 1 diabetes management was derived at 20000/QALY gained. Per-person outputs were inflated to national levels using UK Type 1 diabetes prevalence estimates. ResultsModelled subjects with an HbA(1c) of 86mmol/mol (10.0%) were associated with discounted lifetime per-person costs of 23795; 12649 of which may be avoided by maintaining an HbA(1c) of 42mmol/mol (6.0%). Combined with estimated QALY gains of 2.80, an HbA(1c) of 42mmol/mol (6.0%) vs. 86mmol/mol (10.0%) was associated with a 68621 per-person net monetary benefit. Over 1year, unit reductions in BMI produced 120 per-person net monetary benefit, and up to 197 pound for the avoidance of one non-severe hypoglyceamic event. ConclusionsMaintained reductions in HbA(1c) significantly alleviate the burden associated with Type 1 diabetes in the UK. Given the influence of weight and hypoglycaemia on health economic outcomes, they must also be key considerations when assessing the value of Type 1 diabetes technologies in clinical practice.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?